9 jan 2023
JPMorgan presentation
Potential for indication expansion: Literature reports of CAIX expression
Glioblastoma Multiforme
Nasopharyngeal Carcinoma
Non-Small Cell Lung Cancer
Hepatocellular Carcinoma
Gastric Cancer
Pancreatic Ductal Adenocarcinoma
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Esophageal Cancer
Small Cell Lung Cancer
Cholangio-carcinoma
Soft Tissue Sarcoma
Epithelial Ovarian Cancer
Colorectal Cancer
Ann: Phase II study for indication expansion of TLX250-CDx doses, page-7
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.55 |
Change
-0.450(2.50%) |
Mkt cap ! $5.872B | |||
| Open | High | Low | Value | Volume |
| $17.90 | $17.95 | $17.42 | $21.96M | 1.248M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 17117 | $17.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.57 | 2880 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |